文献速递心律失常冠心病

抗凝房颤患者的心肌梗死风险

Risk of Myocardial Infarction in Anticoagulated Patients With Atrial Fibrillation.
PubMed 文献 · J Am Coll Cardiol · 2018-01-01

基于丹麦健康登记对31,739例房颤患者按初始口服抗凝药分层,用Cox回归估计心肌梗死住院与死亡的标准化1年绝对风险。VKA的1年心梗风险为1.6%,阿哌沙班、达比加群、利伐沙班均为1.1%–1.2%;DOAC之间无显著差异,而各DOAC相对VKA均显著降低心梗风险。

要点

  • 房颤患者中DOAC的1年心梗绝对风险低于VKA
  • 三种DOAC之间心梗风险无显著差异
  • 该研究为观察性设计,不能直接推断因果

核心结论

  • 在房颤患者中,DOAC之间心梗风险无显著差异,各DOAC相对VKA均与心梗风险显著降低相关。

研究设计与样本

  • 丹麦健康登记队列研究,纳入31,739例房颤患者(中位年龄74岁,47%女性),按初始口服抗凝药分层,用Cox回归估计心梗住院与死亡的标准化1年绝对风险。

主要发现

  • VKA的标准化1年心梗风险为1.6%(95%CI 1.3–1.8),阿哌沙班1.2%(95%CI 0.9–1.4),达比加群1.2%(95%CI 1.0–1.5),利伐沙班1.1%(95%CI 0.8–1.3)。
  • DOAC之间风险差异无统计学意义:达比加群vs阿哌沙班0.04%(95%CI -0.3–0.4),利伐沙班vs阿哌沙班0.1%(95%CI -0.4–0.3),利伐沙班vs达比加群-0.1%(95%CI -0.5–0.2)。
  • DOAC相对VKA的风险差异均显著:阿哌沙班-0.4%(95%CI -0.7至-0.1),达比加群-0.4%(95%CI -0.7至-0.03),利伐沙班-0.5%(95%CI -0.8至-0.2)。

临床怎么用

  • 对房颤抗凝患者评估心梗风险时,可参考DOAC相对VKA心梗风险较低的观察性证据。
  • DOAC之间选择可更多依据出血风险、肾功能与依从性等因素。

局限性

  • 为观察性登记研究,按初始抗凝药分组,可能存在残余混杂与适应证偏倚。
  • 仅报告1年标准化绝对风险,未涉及长期随访与随机对照验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Evidence is conflicting as to the efficacy of direct oral anticoagulation (DOAC) and vitamin K antagonist (VKA) for prevention of myocardial infarction (MI). OBJECTIVES: This study aimed to investigate the risk of MI associated with the use of apixaban, dabigatran, rivaroxaban, and VKA in patients with atrial fibrillation. METHODS: Patients with atrial fibrillation were identified using Danish health care registers and stratified by initial oral anticoagulant treatment. Standardized absolute 1-year risks were estimated based on Cox regression for hazard rates of MI hospitalizations and mortality. Reported were absolute risks separately for the oral anticoagulation treatments and standardized to the characteristics of the study population. RESULTS: Of the 31,739 patients included (median age, 74 years; 47% females), the standardized 1-year risk of MI for VKA was 1.6% (95% confidence interval [CI]: 1.3 to 1.8), apixaban was 1.2% (95% CI: 0.9 to 1.4), dabigatran was 1.2% (95% CI: 1.0 to 1.5), and rivaroxaban was 1.1% (95% CI: 0.8 to 1.3). No significant risk differences were observed in the standardized 1-year risks of MI among the DOACs: dabigatran versus apixaban (0.04%; 95% CI: -0.3 to 0.4), rivaroxaban versus apixaban (0.1%; 95% CI: -0.4 to 0.3), and rivaroxaban versus dabigatran (-0.1%; 95% CI: -0.5 to 0.2). The risk differences for DOACs versus VKA were all significant: -0.4% (95% CI: -0.7 to -0.1) for apixaban, -0.4% (95% CI: -0.7 to -0.03) for dabigatran, and -0.5% (95% CI: -0.8 to -0.2) for rivaroxaban. CONCLUSIONS: No significant risk differences of MI were found in the direct comparisons of DOACs, and DOACs were all associated with a significant risk reduction of MI compared with VKA.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Lee CJ, Gerds TA, Carlson N, et al. Risk of Myocardial Infarction in Anticoagulated Patients With Atrial Fibrillation. J Am Coll Cardiol. 2018. PMID: 29957227. doi:10.1016/j.jacc.2018.04.036

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。